Research & KnowledgeEvent: September 8, 2026
AstraZeneca published findings from the OBERON and TITANIA Phase III trials, adding to evidence supporting a potential biologic treatment for chronic obstructive pulmonary disease.
Published
Signal category
Research & Knowledge
Quote
“Newly published findings from the OBERON and TITANIA Phase III trials add to the growing body of evidence supporting a potential biologic treatment for chronic obstructive pulmonary disease.”
— Robert Fogel, MD|AstraZeneca team
Company
- Industry
- Pharmaceutical Manufacturing
- Location
- Cambridge, GB
- Company size
- 82,045 employees
We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com. Community Guidelines: bit.ly/2MgAcio